| 1. | StockCats12 | |
| 2. | ItsNewman | |
| 3. | levawill000 | |
| 4. | 7998mom | |
| 5. | wenday47 |
Top Board Researchers
These are the top researchers based on quality of posts as voted by board members. Typically they know their stuff and are a great
way to catch up on what the company is all about.
HOW DO I BECOME ONE?
Just do great research! As other members approve of your posts, you earn points that move you up the ranks.| 1. | spottedgecko7 06/13/2018 Phase 3 data in the online Journal of the American Academy of Dermatology show Aclaris' ESKATA™ is safe and effective in treating persons with raised seborrheic keratoses |
| 2. | levawill000 02/08/2018 WOW! check out this PT |
| 3. | StockCats12 04/03/2018 Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 4. | StockCats12 12/01/2017 5 Biotech and Pharma Stocks with FDA Catalysts this December |
| 5. | ItsNewman 01/08/2018 Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts |
| 6. | 7998mom 03/20/2018 Announces a publication in the Journal of Experimental Medicine |
| 7. | levawill000 03/10/2018 $ACRS in the news |
| 8. | levawill000 04/06/2018 Aclaris Therapeutics Partners with Cipher Pharmaceuticals to seek regulatory approval and commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses in Canada |
| 9. | ItsNewman 03/21/2018 Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine |
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW
Aclaris Therapeutics, Inc.
- ACRS
- Public Stock Message Board
Filtering by:
-
To use your chart in a post, click the
icon above the chart. From there you can get the chart link or download the image.